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Background/aim: Remdesivir, which was first developed for the treatment of Ebola disease but failed to meet expectations, has become
hope in the fight against the COVID-19 pandemic. This study aimed to evaluate risk factors for mortality and prognosis of adult
moderate/severe COVID-19 patients treated with remdesivir, and safety and tolerability of 5 days of remdesivir treatment.
Materials and methods: This multicenter prospective observational study was conducted in 14 centers in Turkey. Pregnancy or
breastfeeding, multiorgan failure, or usage of vasopressors for septic shock, ALT > 5 × the upper limit of the normal range, or eGRF <30
mL/min or dialysis and receiving favipiravir were the exclusion criteria of the study.
Results: Among 500 patients, 494 patients were included in the study. On admission, 392 (79.3%) patients had moderate and 102
(20.6%) patients had severe COVID-19. The 28-day mortality was 10.1%. The median of the scores of the seven-category ordinal scale
assessed on days 0, 3, 5, 7 were 4 and 3 on day 14. When the survival status of the patients was evaluated according to the time between
the remdesivir start date and the end date of the symptoms, no statistically significant difference was found between the medians of the
groups (p = 0.404). In multivariable analysis, age (OR, 1.05; 95%CI, 1.02–1.08; p = 0.003), SpO2 level on admission (OR, 3.03; 95%CI,
1.35–6.81; p = 0.007), heart rate (OR, 2.48; 95%CI, 1.01–6.07; p = 0.047), follow-up site at the hospital (clinic/ICU) (OR, 26.4; 95%CI,
11.6–60.17; p < 0.001) were independently associated with increased mortality. Grade 3 adverse event (AE) was observed in 4 (0.8%)
patients. None of the patients experienced grade 4 or 5 AEs.
Conclusion: Remdesivir is a safe and well-tolerated drug and older age, low SpO2 level on admission, tachycardia, and ICU admission
are independently associated with increased mortality among patients with moderate/severe COVID-19 receiving remdesivir treatment.
Key words: COVID-19, remdesivir, antiviral, treatment, mortality
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1. Introduction
The second pandemic of the 21st century has directed
almost all resources of medicine to treatment and
vaccination studies. Although tremendous success has
been achieved in terms of vaccines for COVID-19, it is
still not possible to say the same for the antiviral treatment.
SARS-COV-2 often causes a mild upper respiratory tract
infection; nevertheless, it is a complicated disease with a
hyperinflammatory response that becomes a challenge
to physicians in many respects. Although there are
treatments that have been shown to be effective in the host
inflammatory response phase, antiviral treatments are
particularly important in the early viral response phase of
the disease to be able to block viral replication.
Remdesivir, a nucleotide analogue of adenosine
5-monophosphate, is a broad-spectrum antiviral against
RNA viruses like severe acute respiratory syndrome
coronavirus 1 (SARS-CoV-1), Middle East respiratory
syndrome virus (MERS-CoV), and Ebola virus [1]. It is a
potent inhibitor of viral RNA-dependent RNA polymerase,
which causes the termination of RNA transcription after
it is taken up by the virus into RNA strands. Early in the
COVID-19 pandemic, researchers reported that remdesivir
has an in vitro activity against SARS-CoV-2 [2], and
then remdesivir became one of the arms of randomized
controlled studies like Solidarity and Adaptive COVID-19
Treatment Trial (ACTT-1). Early reports of the ACTT-1
trial in April 2020 showed that remdesivir shortens the
duration of complaints (11 vs 15 days) in COVID-19
cases with pneumonia. The final results of the ACTT-1
study concluded that remdesivir was superior to placebo
in shortening the time to recovery of adults who were
hospitalized due to COVID-19 and carried symptoms of
lower respiratory tract infection [3], which resulted in its
approval by the Food and Drug Administration (FDA) as
the only antiviral drug for the treatment of hospitalized
COVID-19 patients.
This study aimed to evaluate: 1-the prognosis of adult
patients who have been diagnosed with moderate to severe
COVID-19 and treated with remdesivir, 2-risk factors for
mortality among moderate to severe COVID-19 patients
treated with remdesivir, 3-safety and tolerability of 5 days
of remdesivir treatment.
2. Materials and methods
2.1. Study design
This multicenter prospective observational study was
conducted in 14 referral centers for COVID-19 in Turkey
in compliance with the Declaration of Helsinki and Good
Clinical Practice. The study was approved by the Ministry
of Health, the ethics board of Ankara City Hospital (No:

E1-20-811), and the National Regulatory Agency; and it
was conducted between June 30, 2020, and March 05, 2021.
A central database was implemented for data collection,
and an independent data and safety monitoring board
assessed the integrity of the data. All patients provided
written informed consent. In the cases where a patient
was unable to provide consent, it was obtained from the
patient’s legal representative.
2.2. Patients and treatment schedule
Moderate and severe COVID-19 patients were identified
according to the WHO guideline1.
Inclusion criteria: Patients meeting all of the following
criteria were included in the study:
• Diagnosis of COVID-19 with PCR and/or other
accepted serological methods accompanied by appropriate
clinical complaints and/or findings consistent with
COVID-19 in chest CT,
• One of the following in addition to fever or signs of
respiratory infection:
o Respiratory rate >30/min,
o Severe respiratory distress (dyspnea, use of extra
respiratory muscles),
o More than 50% involvement of lung parenchyma in
CT,
o SpO2 ≤ 94% in room air,
• ≥18 years old.
Exclusion criteria: Patients meeting any of the following
criteria were excluded from the study:
• Pregnant or breastfeeding mothers,
• Patients aged <18,
• Multiorgan failure,
• Using vasopressors for septic shock,
• ALT > 5 × the upper limit of the normal range,
• eGRF < 30 mL/min or dialysis or continuous venovenous hemofiltration,
• Using favipiravir.
Patients were intravenously administered remdesivir
as a 200-mg loading dose on the first day and 100-mg
maintenance doses on days 2 through 5. Demographic
features (e.g., age, sex), symptoms with their onset times,
comorbidities, other medications, vital signs, and other
physical examination results were recorded.
The clinical assessment was recorded on day 0, day 3,
day 5, day 7, and day 14 if the patient was still hospitalized.
Patients’ clinical status was categorized as one of a
seven-category ordinal scale [4]: 1: not hospitalized,
resumed normal activities; 2: not hospitalized, unable
to resume normal activities; 3: hospitalized, does not
require supplemental oxygen; 4: hospitalized, requires
supplemental oxygen; 5: hospitalized, requires nasal highflow oxygen therapy, noninvasive mechanical ventilation,

Clinical management of COVID-19. Website https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19 (accessed 25
December 2021).
1
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or both; 6: hospitalized, requires ECMO, invasive mechanical
ventilation, or both; and 7: death.
Polymerase chain reaction (PCR) test was performed on
day 0, day 3, day 5, day 7, and on day 14 if the patient was
still hospitalized.
All serious adverse events and adverse events of grade 3
or 4 that represented an increase in severity when compared
to day 1 were recorded.
2.3. Study outcomes
The primary outcome of this study was to evaluate the
clinical status of the patients on day 28, who were diagnosed
with moderate to severe COVID-19 and were treated with
remdesivir. The secondary outcomes were independent
mortality risk factors among moderate to severe COVID-19
patients who have been treated with remdesivir and
evaluation of safety, in particular adverse events that lead
to premature treatment discontinuation of remdesivir. The
number and the characteristics of adverse events (AE) and
serious adverse events (SAE) were monitored. Adverse
events classification version 5.0 of the National Cancer
Institute Common Terminology Criteria for Adverse Events
was used.
2.4. Statistical analysis
Statistical analyses were performed using IBM SPSS V25
(SPSS Statistics for Windows, v25.0, IBM Corp, Armonk,
NY). Descriptive features of patients are presented as
number, percentage, mean ± standard deviation, and
median (minimum–maximum) values. Before the statistical
analyses, the conformity of the continuous variables to the
normal distribution was checked according to the groups,
and the analyses were carried out with parametric tests in
cases where the conformity to the normal distribution was
achieved, and with nonparametric tests when the conformity
to the normal distribution was not achieved. Pearson’s
chi-squared test or Fisher’s exact test was used to evaluate
categorical data. Independent sample t-test/Mann–Whitney
U test was used for mean/median comparisons of two
independent groups. Laboratory results and symptoms of the
volunteers were recorded repeatedly. Nonparametric tests
were not used for repeated measurements so that the findings
would not be misleading due to missing observations, and
only comparisons of the first measurements according to the
survival status were reported.
Logistic regression analysis (backward-LR method) was
used for the multivariable assessment of the relationship
between mortality and the various risk factors. The odds
ratio (OR) and the 95% confidence interval (CI) were also
calculated. A p-value of less than 0.05 was considered
statistically significant.
3. Results
Demographic and clinical characteristics of the patients are
given in Table 1. Among 500 patients who consented to
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the trial, only 6 patients were excluded from the analysis
since they used remdesivir for a shorter period than
planned (2 patients 1 day, 4 patients 2 days). Among the
remaining patients, 305 (61.7%) were male and 189 were
female. On admission, 392 (79.3%) patients had moderate
and 102 (20.6%) patients had severe COVID-19. At the
time of admission, 452 (91.3%) patients were hospitalized
in the clinic and 43 (8.7%) were admitted to the intensive
care unit (ICU). Among 452 patients, 85 (18.8%) patients
were transferred to the ICU during the follow-up. The 28day mortality was 10.1% (50 patients) (2.5% for patients
followed in the clinic, 47.1% for the patients followed in
the ICU). Four patients were still hospitalized on day 28.
SARS-CoV-2 PCR test was positive in 253 (72.3%)
patients on admission, 134 patients (42.5%) on the 3rd-day
visit, 90 patients (30.5%) on the 5th-day visit, 45 patients
(23.0%) on the 7th-day visit, and 8 patients (19.5%) on the
14th day visits. The mortality rate was found to be high in
patients with positive PCR test results on admission (p =
0.001).
When the patients were evaluated in terms of
comorbidities, hypertension (41.3%) was the most
frequent disease, which was followed by diabetes mellitus
(29.4%) and chronic cardiac disease (CCD) (21.9%).
The median time from illness onset to admission was 4
days. On chest CT, 12 (3.0%) patients had unilateral, 372
(93.5%) had bilateral ground-glass opacity. In addition to
remdesivir, 140 (28.1%) patients received dexamethasone,
117 (23.4%) patients received methylprednisolone, 5 (1%)
patients received immune plasma, and 5 (1%) patients
received tocilizumab.
The median of the scores of the seven-category ordinal
scale assessed on days 0, 3, 5, 7 were 4 and 3 on day 14.
The median time to symptom resolution from the first
administration of remdesivir was 5 [3-9] days and the
median time to negative PCR result was 6 [4-9] days.
There was no statistically significant difference between
male and female patients in terms of age and 28-day
mortality (p=0.173 and 0.930, respectively). The mortality
rate in patients with diabetes, renal failure, and chronic
lung disease was high (p=0.017, p < 0.001, and p = 0.020,
respectively).
When the survival status of the patients was evaluated
according to the time between the remdesivir start date and
the end date of the symptoms, no statistically significant
difference was found between the medians of the groups (p
= 0.404). No statistically significant correlation was found
between the time to PCR negativity and mortality.
Univariate analysis revealed 11 risk factors to be
statistically significant predictors of mortality. The logistic
regression model has included 11 regressors that were
age, sex, renal failure, diabetes, chronic cardiac disease,
chronic lung disease, dyspnea on admission, follow-up

HASANOĞLU et al. / Turk J Med Sci
Table 1. Baseline characteristics of the patients.
All patients

Died (n, %)

Survived (n, %)

p-value

62.0 [21.0–97.0]

71.0 [26.0–92]

61.0 [21.0–97.0]

U = 7010.0 p < 0.001

18–30 n (%)

15 (100)

1 (6.7)

14 (93.3)

31–45 n (%)

54 (100)

3 (5.6)

51 (94.4)

46–65 n (%)

225 (100)

16 (7.1)

209 (92.9)

≥66 n (%)

196 (100)

30 (15.3)

166 (84.7)

Male n (%)

301 (100)

31 (10.3)

270 (89.7)

Female n (%)

189 (100)

19 (10.1)

170 (89.9)

X2 = 0.008
p = 0.930

Any comorbidity

314 (100)

41 (13.1)

273 (86.9)

X2 = 8.165 p = 0.004

Hypertension

204

25 (%12.3)

179 (%87.7)

p = 0.205

Diabetes

144

22 (%15.3)

122 (%84.7)

p = 0.017

Chronic cardiac disease

108

19 (%17.6)

89 (%82.4)

p = 0.004

Chronic pulmonary disease

73

13 (%17.8)

60 (%82.2)

p = 0.020

Renal failure

16

6 (%37.5)

10 (%62.5)

p = 0.001

Malignancy

20

4 (%20)

16 (%80)

p = 0.139

Fever

160 (100)

18 (11.2)

142 (88.8)

p = 0.594

Cough

283 (100)

28 (9.9)

255 (90.1)

p = 0.791

Dyspnea

97 (100)

17 (17.5)

80 (82.5)

p = 0.008

Sore throat

35 (100)

3 (8.6)

32 (91.4)

p = 0.741

Headache

52 (100)

5 (9.6)

47 (90.4)

p = 0.882

Myalgia

100 (100)

12 (12.0)

88 (88.0)

p = 0.506

Diarrhea

43 (100)

2 (4.7)

41 (95.3)

p = 0.208

Nausea/vomiting

56 (100)

5 (8.9)

51 (91.1)

p = 0.738

Heart rate > 100/min

72 (100)

16 (22.2)

56 (77.8)

X2 = 15.03 p < 0.001

Demographic characteristics
Age, years (median, min–max)
Age groups
X2 = 9.396
p = 0.024

Sex

Preexisting conditions

Clinical features

site (clinic or ICU), heart rate (>100/min), presence of
any comorbidity, and SpO2 (<90%) on admission. The
model with the backward LR method was completed
in 8 steps. Result of the last step is presented in Table 2.
The Hosmer–Lemeshow test results showed that the last
model adequately fits the data with X2 = 4.412 and p =
0.818 values. The correct classification rate (Accuracy) of
the logistic regression model was found to be 92.1% (Table
3). In multivariable analysis, the following variables were
independently associated with increased mortality: age
(OR, 1.05; 95% CI, 1.02–1.08; p = 0.003), SpO2 level on
admission (OR, 3.03; 95% CI, 1.35–6.81; p = 0.007), heart
rate (OR, 2.48; 95% CI, 1.01–6.07; p = 0.047), follow-up
site at the hospital (clinic or ICU) (OR, 26.4; 95% CI, 11.6–
60.17; p < 0.001) (Table 2).

A total of 12 drug-related AEs were recorded. Grade
3 AE was observed in 4 (0.8%) patients. None of the
patients experienced grade 4 or 5 AEs. All the observed
AEs were transaminase elevation. None of the AEs caused
remdesivir discontinuation.
4. Discussion
Remdesivir, which was first developed for the treatment of
Ebola disease but failed to meet expectations, has become
hope in the fight against the COVID-19 pandemic.
Considering that the preliminary results of its first study
were announced with the presence of the President of
the United States, remdesivir has been one of the few
particularly popular drugs in the history of medicine.
Although hopes that remdesivir could be a game-changer
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Table 2. Logistic regression model for mortality prediction.

B

S.E.

Wald

df

p-value

OR

Age

0.046

0.016

8.536

1

0.003

SpO2 level on admission

1.107

0.414

7.167

1

Hearth rate

0.908

0.457

3.958

1

Follow up site at the hospital

3.273

0.420

60.629

Constant

–7.185

1.163

38.178

95% CI for OR
Lower

Upper

1.047

1.015

1.080

0.007

3.026

1.345

6.807

0.047

2.481

1.014

6.071

1

<0.001

26.397

11.581

60.169

1

<0.001

0.001

a. Variable(s) entered on step 1: Sex (male/female), age (continious), any comorbidity (no/yes), diabetes mellitus (no/yes), chronic cardiac disease (no/yes),
chronic lung disease (asthma, /COPD etc.) (no/yes), dispnea (no/yes), SpO2 level on admission to the hospital (intermediate level/severe level), heart rate
follow-up site at the hospital (clinic/ICU), renal failure(no/yes), p < 0.05 significance level
(≤100/100<),
Table 3. Classification table of the logistic regression model.
Predicted
Observed

Last step

Survival

Survival

Survived

Died

Percentage
correct

Survived

423

12

97.2

Died

26

19

42.2

Overall percentage

in the treatment of COVID-19 were more widespread
at the beginning of the pandemic, this notion weakened
over time. Now, recommendations regarding the use of
remdesivir for the treatment of COVID-19 vary. In October
2020, FDA approved remdesivir use in hospitalized
COVID-19 patients ≥ 12 years old and weighing ≥ 40
kg, and Veklury became the first drug that received
FDA approval for the treatment of COVID-19. NIH
and Infectious Diseases Society of America recommend
remdesivir for the treatment of hospitalized patients who
require supplemental oxygen2,3. Opposingly, the WHO
recommends against the use of remdesivir4. WHO bases
this recommendation on the results of its open-label
adaptive Solidarity trial, which is the largest randomized
controlled study of remdesivir with 5472 patients from 405
hospitals in 30 countries [5]. Solidarity revealed that 10
days of remdesivir treatment did not reduce the length of
stay in the hospital, initiation of ventilation, and mortality
compared to the standard of care. Although a huge number

92.1

of patients were included in Solidarity, it did not affect the
decisions of the FDA, EMA, and many other scientific
societies recommending the use of remdesivir. Solidarity’s
main shortcoming was the lack of categorization of
patients in terms of how they received oxygen (i.e. low or
high flow). Instead, patients were classified according to
whether they did or did not receive oxygen therapy or if
they required mechanical ventilation.
Results of the first randomized double-blind placebocontrolled study of remdesivir were reported by Wang et
al. from China. Although the study could not reach the
planned sample size due to the early control of the pandemic
in China, they found that remdesivir has no statistically
significant effect on mortality or clinical improvement
compared with standard of care [6]. This study included
less severe patients when compared to ACTT-1 which
advocated the use of remdesivir. Contrary to intuition,
this difference did not offer an advantage for remdesivir
in the study of Wang et al. [6,7]. Recently published

IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Website https://www.idsociety.org/practice-guideline/covid-19guideline-treatment-and-management (accessed 4 October 2021)
2

Therapeutic Management COVID-19 Treatment Guideline. Website https://www.covid19treatmentguidelines.nih.gov/management/clinicalmanagement/hospitalized-adults--therapeutic-management/ (accessed 4 October 2021).
3

COVID-19 Clinical management: living guidance. Website https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2 (accessed 23
December 2021).
4
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Discovery study, which is a phase 3 multicenter RCT of
remdesivir, concluded that remdesivir did not improve
the clinical status of the hospitalized COVID-19 patients
neither on day 15 nor 29 and did not reduce mortality
and SARS-CoV-2 viral load [8]. ACTT-1 trial, which was
conducted by NIH and enrolled 1062 patients (15% mild/
moderate disease, 85% severe disease) from 60 hospitals,
reported that remdesivir has shortened the recovery time
(10 days vs 15 days for placebo). The mortality rate was
found to be 11.4% in the remdesivir group and 15.2% in
the placebo group on day 29 [3]. The mortality rate in our
study was 10.1% on day 28, 14% in the study by Wang et
al., and 12.5% in the Solidarity trial [5,6]. It is difficult to
compare the main outcome of mortality results since the
study designs and study populations were quite different.
We included moderate and severe COVID-19 patients,
and 62.9% of the patients had at least 1 comorbidity and
61.4% of the patients were male. This heterogeneity caused
inconsistent data regarding the efficacy of remdesivir.
There are as many metaanalyses as clinical studies of
remdesivir in the literature, but these metaanalyses should
be interpreted very carefully as well [9–14]. Various
randomized controlled studies do not offer uniform
findings and have inconsistent results in terms of clinical
improvement. In addition, the inability to collaborate and
share high-quality data due to the increased workload of
physicians in the pandemic was also effective. The Living
Project, which is a metaanalysis of 2 trials evaluating the
treatments of COVID-19, concluded that there is evidence
of a positive effect of remdesivir on serious adverse events
when compared to the placebo group, but no difference
in mortality or nonserious adverse events [15]. Another
living systematic review and metaanalysis which includes
7767 patients from 5 randomized controlled studies
worldwide reported that remdesivir probably provides
little or no difference in mortality, a slight reduction in
the need for ventilation while possibly improving the rate
of recovery and serious adverse events. For patients not
requiring mechanical ventilation, a 5-day course may be
preferred instead of the 10-day course for greater benefits,
fewer harms, and lower costs [9].
Although the antiviral efficacy of remdesivir had been
demonstrated by preclinical studies, not all clinical studies
supported these data. In our study, the SARS-CoV-2 PCR
test was positive in 253 (72.3%) patients on admission and
8 patients (19.5%) on the 14th-day visits. In a study from
Italy, in all 21 patients, RT-PCR was found to be negative
on a median of 12 days after the start of remdesivir
treatment [16]. Wang et al. reported that remdesivir did
not reduce viral load and detectability of SARS-CoV-2
RNA [6]. In our study, a numerically lower detectability of

SARS-CoV-2 RNA on day 14th was observed, and it may
reflect the natural course of the disease as well.
While the second year of the pandemic was about to
end, risk factors associated with mortality in COVID-19
were revealed with thousands of articles published in the
literature. However, there are not many studies evaluating
these risk factors in patients receiving remdesivir. A
metaanalysis evaluating indicators of severe COVID-19
among 69,762 patients from 88 articles, found that older
age, dyspnea, and lower SpO2 (<89%) on admission,
cardiovascular
disease,
cerebrovascular
disease,
chronic lung disease, chronic kidney disease, diabetes,
hypertension, cancer, and smoking are risk factors for
mortality [17]. Another meta-analysis revealed similar risk
factors regarding mortality among 423,117 patients from
42 studies and reported the pooled prevalence of mortality
among hospitalized COVID-19 patients as 17.62% [18]. In
a study from Turkey, which evaluates different treatment
regimens including remdesivir (n: 17), researchers reported
that the most significant factor for increased mortality is
ICU admission [19]. In our study population of moderate/
severe COVID-19 patients treated with remdesivir; male
sex, renal failure, diabetes, chronic cardiac disease, chronic
lung disease, dyspnea on admission, and presence of any
comorbidity were found as risk factors for mortality only
in univariate analysis. However, in multivariable analysis,
age (OR, 1.05; 95% CI, 1.02–1.08; p = 0.003), SpO2 level
on admission (OR, 3.03; 95% CI, 1.35–6.81; p = 0.007),
heart rate (OR, 2.48; 95% CI, 1.01–6.07; p = 0.047), followup site at the hospital (clinic or ICU) (OR, 26.4; 95% CI,
11.6–60.17; p < 0.001) were independently associated with
increased mortality.
This study also evaluated the safety and tolerability of
remdesivir. A total of 12 drug-related AEs were recorded.
Grade 3 AE was observed in 4 (0.8%) patients. None
of the patients experienced grade 4 or 5 AEs. All the
observed AEs were transaminase elevation. According
to the product information, nausea and elevation of liver
enzymes are the most observed adverse reactions5. None
of the AEs caused remdesivir discontinuation. Our study
demonstrated that remdesivir is safe and well-tolerated,
in accordance with the current literature [20,21]. Drugrelated adverse reactions are observed more commonly in
10 days of remdesivir treatment. Antinori et al. reported
that elevation of liver enzymes is observed in 42.8% of
the patients and one-third of the patients enrolled were
unable to complete the 10-day remdesivir treatment due
to the presence of AEs [16]. Grein et al. reported similar
rates of AEs with a 10-day course of remdesivir [7]. In a
randomized, open-label, phase 3 study of remdesivir, 30%
of the 200 patients enrolled in the 5-day group experienced

Veklury Prescribing Information. Website https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf (Accessed 12
December 2021)
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no AE of grade 3 or higher [22]. In general, the most
observed adverse events were nausea, acute respiratory
failure, elevated ALT, and constipation. The ratio of
patients who had to discontinue treatment due to adverse
events was 4% in the 5-day group and 10% in the 10-day
group. However, this comparison is questionable owing
to the fact that some studies categorize acute respiratory
failure as an adverse event, whereas some do not.
Moreover, since COVID-19 also causes acute respiratory
failure, detecting a drug-induced acute respiratory failure
is subjective. Furthermore, the elevation of liver enzymes,
the most common drug-related adverse event, can also
be associated with the COVID-19. Therefore, it is very
important to interpret the results related to adverse events
carefully.
This study has several limitations. The first and the most
important one is that the study does not include a placebo
or an alternative treatment arm. Therefore, a comparison
of remdesivir treatment with the standard of care could
not be performed. Due to this limitation, the possibility
that patients who clinically improved after remdesivir
treatment could have improved even without any treatment
cannot be ruled out. Secondly, we included only moderate
to severe COVID-19 patients; hence, the results cannot
be generalized for all patient groups. Thirdly, the trend of
the SARS-CoV-2 viral load under remdesivir treatment
was not evaluated. Fourthly, the study was conducted in

14 centers from different cities across Turkey. Since cutoff values for laboratory parameters were different across
centers, some laboratory parameters that may have turned
out to be outcome predictors were not recorded.
In conclusion, since the most important stage of the
pathogenesis is viral replication, there is no doubt that
antivirals fit in the center of the puzzle of COVID-19
treatment. Remdesivir is the first drug that received
FDA approval for treatment of COVID-19, but different
societies have diverse recommendations regarding the
use of remdesivir. According to this study, remdesivir is
a safe and well-tolerated drug, and older age, low SpO2
level on admission, tachycardia, and ICU admission are
independently associated with increased mortality among
patients with moderate/severe COVID-19 receiving
remdesivir treatment.
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